IMNN Overview

Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.

Wall Street analysts forecast IMNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMNN is12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Imunon Inc revenue for the last quarter amounts to 0.00 USD, decreased

Imunon Inc. EPS for the last quarter amounts to -1.01 USD, decreased -76.94

Imunon Inc (IMNN) has 25 emplpoyees as of April 01 2026.

Today IMNN has the market capitalization of 9.79M USD.